SERDs in Focus: Optimizing Treatment Strategies in HR+ HER2- Breast Cancer - Episode 6
Insights From SABCS 2024 and Future Directions in Breast Cancer
Dr. Gandhi and Dr. Clifton explore clinical decision-making and sequencing for selective estrogen receptor degraders (SERDs), antibody-drug conjugates (ADCs), and other targeted therapies in hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), balancing efficacy, safety, and patient characteristics, while highlighting promising data from the 2024 San Antonio Breast Cancer Symposium (SABCS) and the role of precision medicine in improving outcomes and patient experiences.
Video content above is prompted by the following:
- When considering these SERD trials, emerging data with ADCs, and other targeted therapies (eg, inavolisib), how are you approaching clinical decision-making and sequencing in your patients?
- How do you anticipate sequencing SERDs in patients who may have received multiple prior lines of endocrine-based therapy?
- How do you envision optimally sequencing SERDs, ADCs, and other treatment options? How would you balance considerations about efficacy, safety, mechanism of action, and patient characteristics when determining the optimal treatment sequence?
- Please highlight the most exciting data or studies from SABCS that you find most promising in terms of improving outcomes in HR+/HER2– mBC.
- How has precision medicine improved outcomes and the patient experience from your perspective?